Want to see TLSI full AI Analyst Report?
TLSI Stock Chart & Stats
$4.65
-$0.05(-0.97%)
At close: 4:00 PM EST
$4.65
-$0.05(-0.97%)
Day’s Range― - ―
52-Week Range$2.20 - $7.95
Previous CloseN/A
Volume4.84K
Average Volume (3M)421.74K
Market Cap
$264.71M
Enterprise Value$187.19
Total Cash (Recent Filing)$56.55M
Total Debt (Recent Filing)$34.49M
Price to Earnings (P/E)―
Beta0.83
Next Earnings
Aug 06, 2026EPS Estimate
-0.16Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.41
Shares Outstanding61,416,534
10 Day Avg. Volume272,778
30 Day Avg. Volume421,743
Financial Highlights & Ratios
PEG Ratio-0.08
Price to Book (P/B)-10.14
Price to Sales (P/S)7.60
P/FCF Ratio-18.14
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$9.00Price Target Upside93.55% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.32
Revenue Forecast (FY)$53.67M
Bulls Say, Bears Say
Bulls Say
High Gross MarginsConsistently high mid-80s gross margins indicate strong unit economics for the TriNav system and PEDD services. Durable contribution margins support scalability, enable reinvestment in sales and R&D, and improve the path to operating leverage as revenue grows across indications.
Clinical Validation & Evidence BaseRobust real-world and investigator-initiated data materially de-risks the technology's clinical value proposition. Strong outcomes and per‑patient downstream cost avoidance (~$7.7k) enhance payer and provider acceptance, aiding durable adoption across multiple oncology procedures.
Commercial Build & Multi‑indication ExpansionA materially expanded commercial footprint plus ongoing clinical programs across new indications creates multiple, structurally larger revenue pathways. If reps ramp as planned, this supports multi-year top-line growth and diversifies revenue away from single-use liver procedures.
Bears Say
Sharp Revenue Decline & Cash BurnA steep TTM revenue contraction combined with sustained negative operating cash flow means the business is not yet self-funding. Continued cash burn increases reliance on external capital, constraining strategic optionality and making execution on commercial expansion financially sensitive.
Elevated Leverage And Pressured Balance SheetMaterial rise in debt and historically negative equity reduce financial flexibility. High leverage limits capacity for further investment without dilutive financing or costly debt, and raises refinancing and covenant risks if operating performance falters over the medium term.
Regulatory Timing Risk (TriNav Advance Delay)Prolonged FDA timing uncertainty defers revenue tied to TriNav Advance and complicates commercial planning. Regulatory delays create persistent execution risk, delaying payor coverage and clinician adoption that materially affect multi‑year revenue ramp assumptions.
TriSalus Life Sciences News
TLSI FAQ
What was Trisalus Life Sciences, Inc.’s price range in the past 12 months?
Trisalus Life Sciences, Inc. lowest stock price was $2.20 and its highest was $7.95 in the past 12 months.
What is Trisalus Life Sciences, Inc.’s market cap?
Trisalus Life Sciences, Inc.’s market cap is $264.71M.
When is Trisalus Life Sciences, Inc.’s upcoming earnings report date?
Trisalus Life Sciences, Inc.’s upcoming earnings report date is Aug 06, 2026 which is in 15 days.
How were Trisalus Life Sciences, Inc.’s earnings last quarter?
Trisalus Life Sciences, Inc. released its earnings results on May 12, 2026. The company reported $0.03 earnings per share for the quarter, beating the consensus estimate of -$0.158 by $0.188.
Is Trisalus Life Sciences, Inc. overvalued?
According to Wall Street analysts Trisalus Life Sciences, Inc.’s price is currently Undervalued.
Does Trisalus Life Sciences, Inc. pay dividends?
Trisalus Life Sciences, Inc. does not currently pay dividends.
What is Trisalus Life Sciences, Inc.’s EPS estimate?
Trisalus Life Sciences, Inc.’s EPS estimate is -0.16.
How many shares outstanding does Trisalus Life Sciences, Inc. have?
Trisalus Life Sciences, Inc. has 61,416,534 shares outstanding.
What happened to Trisalus Life Sciences, Inc.’s price movement after its last earnings report?
Trisalus Life Sciences, Inc. reported an EPS of $0.03 in its last earnings report, beating expectations of -$0.158. Following the earnings report the stock price went down -41.447%.
Which hedge fund is a major shareholder of Trisalus Life Sciences, Inc.?
Currently, no hedge funds are holding shares in TLSI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
TriSalus Life Sciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$9.00 (93.55% Upside)
$9.00 (93.55% Upside)
Blogger Sentiment
Bullish
TLSI Sentiment 70%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Increased
By 109.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $1.8M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.4%
Last 30 Days ▼ 4.5%
Last 30 Days ▼ 4.5%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-6.30%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
147.96%
Trailing 12-Months
Company Description
Trisalus Life Sciences, Inc.
TriSalus Life Sciences, Inc. is an immunotherapy firm dedicated to the research, development, and market introduction of treatments that leverage the body's immune system, primarily targeting liver and pancreatic cancers. The company's product portfolio includes the TriNav Infusion System, designed for hepatic arterial infusion to treat liver tumors, and the Pancreatic Retrograde Venous Infusion System, which addresses pancreatic tumors. Additionally, TriSalus is advancing SD-101, an investigational immunotherapeutic that incorporates pressure-enabled drug delivery technology. This experimental therapy is currently being explored for its application in hepatocellular carcinoma, intrahepatic cholangiocarcinoma, uveal melanoma with liver metastases, pancreatic ductal adenocarcinoma with liver metastases, colorectal cancer with liver metastases, and primary pancreatic cancers. The company's operations are headquartered in Westminster, Colorado.
TLSI Stock 12 Month Forecast
Average Price Target
$9.00
▲(93.55% Upside)
Technical Analysis
Ownership Overview
28.22% Insiders
6.64% Mutual Funds
22.90% Other Institutional Investors
35.88% Public Companies and
Individual Investors